Phase II trial of spirogermanium and vindesine in malignant glioma.
Fifty-four adults with recurrent malignant glioma were treated on an Eastern Cooperative Oncology Group (ECOG) trial. All had previous radiation therapy, and 70% had previous chemotherapy. They were assigned to either vindesine 3 mg/m2 weekly or spirogermanium 80 mg/m2 three times weekly with escalation to 120 mg/m2. The response was 4% to vindesine, and 8% to spirogermanium. The duration of response was 53 days for a patient who had clinical improvement only, but greater than 151 days and greater than 1066 days for two patients who had achieved a greater than 50% reduction in tumor size by computed tomography (CT). The toxicities were hematologic for vindesine and neurologic for spirogermanium. Neither agent seems to have sufficient efficacy to warrant further trials in previously treated glioma patients.
Alavi
J B
JB
Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia 19104.
Schoenfeld
D
D
Skeel
R T
RT
Kirkwood
R
R
Tsung
L
L
Marsh
J C
JC
D000328:Adult; D000368:Aged; D002528:Cerebellar Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D013141:Spiro Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D014751:Vindesine / Q000009:adverse effects / Q000627:therapeutic use*
D009942:Organometallic Compounds; D013141:Spiro Compounds; C026818:spirogermanium; D014751:Vindesine